| Keywords: |
treatment failure; clinical trial; review; cisplatin; doxorubicin; fluorouracil; patient selection; antineoplastic agents; cancer adjuvant therapy; cancer radiotherapy; pancreas cancer; chemotherapy, adjuvant; pancreatic neoplasms; radiotherapy, adjuvant; cytarabine; methotrexate; antineoplastic agent; cancer immunotherapy; phase 2 clinical trial; thiotepa; vinblastine; digestive system cancer; randomized controlled trials; bleomycin; tamoxifen; stomach cancer; mitomycin c; polysaccharide; phase 3 clinical trial; phase 1 clinical trial; esophagus cancer; floxuridine; stomach neoplasms; portal vein; upper gastrointestinal tract; esophageal neoplasms; endoscopic echography; intravenous drug administration; humans; human; priority journal; picibanil
|
